The BRPTO [INPI] and the Brazilian FDA[ANVISA] issue Ordinance #1/2017 on prior approval of pharmaceutical patent applications under art. 229-C of the Patent Law
Published on April 13 in the Brazilian Federal Official Gazette, Interagency Ordinance #1/2017 enters into force on June 12th. Anti-patent biased, it establishes: i) ANVISA ́s denials under art. 229-C as basis for BRPTO ́s contructive abandonment of patent applications; ii) special pre-grant opposition track for ANVISA, which will halt examination; and iii) anti-patent harmonization […]